(Q35056053)

6 August 2017

1 reference

title

The therapeutic potential of CXCR4 antagonists in the treatment of HIV. (English)

1 reference

6 August 2017

3

Hirokazu Tamamura

1 reference

6 August 2017

Nobutaka Fujii

1

1 reference

6 August 2017

Hideki Nakashima

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Investigational Drugs

6 August 2017

published in

1 reference

6 August 2017

volume

12

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

185-195

1 reference

HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

HIV entry and its inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

A novel anti-HIV synthetic peptide, T-22 ([Tyr5,12,Lys7]-polyphemusin II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

A comparative study of the solution structures of tachyplesin I and a novel anti-HIV synthetic peptide, T22 ([Tyr5,12, Lys7]-polyphemusin II), determined by nuclear magnetic resonance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Molecular cloning and structure of a pre-B-cell growth-stimulating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Effective lowly cytotoxic analogs of an HIV-cell fusion inhibitor, T22 ([Tyr5,12, Lys7]-polyphemusin II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Synthesis and evaluation of bifunctional anti-HIV agents based on specific CXCR4 antagonists-AZT conjugation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Biological and genetic characterization of a human immunodeficiency virus strain resistant to CXCR4 antagonist T134.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

High expression of the chemokine receptor CXCR4 predicts extramedullary organ infiltration in childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

Therapeutic potential of blocking HIV entry into cells: focus on membrane fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.12.2.185

10.1517/13543784.12.2.185

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference